CLYM Reports $110M Private Placement, $19B Revenue, +94% YoY, Subcutaneous Budoprutug Shows Robust B-Cell Depletion, Phase 1b/2a ITP Data Expected June 2026, PrisMN Phase 2 Fast Track Designation Granted, Anticipate Q4 2026 Anti-PLA2R and SLE B-Cell Data, Initiate Multiple-Dose A
Climb Bio, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $11.80
-17% in 7d after detection
Post-detection moves
1h
—
1d
-4.5%
3d
-6.2%
7d
-17%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS